Athersys, Inc. – Product Pipeline Review – H2 2011 by GlobalMarketsDirect

VIEWS: 5 PAGES: 75

More Info
									Athersys, Inc. – Product Pipeline Review




      Athersys, Inc. – Product Pipeline Review – H2 2011


                                                                                          Reference Code: GMDHC02120CDB
                                                                                                 Publication Date: DEC 2011




Athersys, Inc. – Product Pipeline Review – H2 2011                                        GMDHC02120CDB / Published DEC 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                               Page(1)
Athersys, Inc. – Product Pipeline Review




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 5
    List of Figures ................................................................................................................................................................................ 5
Athersys, Inc. Snapshot...................................................................................................................................................................... 6
    Athersys, Inc. Overview ................................................................................................................................................................. 6
    Key Information ............................................................................................................................................................................. 6
    Key Facts....................................................................................................................................................................................... 6
Athersys, Inc. – Research and Development Overview ..................................................................................................................... 7
    Key Therapeutic Areas .................................................................................................................................................................. 7
Athersys, Inc. – Pipeline Review ........................................................................................................................................................ 9
    Pipeline Products by Stage of Development ................................................................................................................................. 9
    Pipeline Products – Monotherapy ............................................................................................................................................... 10
Athersys, Inc. – Pipeline Products Glance........................................................................................................................................ 11
    Athersys, Inc. Clinical Stage Pipeline Products ........................................................................................................................... 11
        Phase II Products/Combination Treatment Modalities ............................................................................................................ 11
        Phase I Products/Combination Treatment Modalities ............................................................................................................. 12
    Athersys, Inc. – Early Stage Pipeline Products............................................................................................................................ 13
        Pre-Clinical Products/Combination Treatment Modalities ....................................................................................................... 13
        Discovery Products/Combination Treatment Modalities.......................................................................................................... 14
Athersys, Inc. – Drug Profiles ........................................................................................................................................................... 15
    5HT2C Agonist ............................................................................................................................................................................ 15
        Product Description................................................................................................................................................................. 15
        Mechanism of Action ............................................................................................................................................................... 15
        R&D Progress ......................................................................................................................................................................... 15
    ATHX-105 .................................................................................................................................................................................... 16
        Product Description................................................................................................................................................................. 16
        Mechanism of Action ............................................................................................................................................................... 16
        R&D Progress ......................................................................................................................................................................... 16
    Histamine H3 Receptor Antagonists ............................................................................................................................................ 17
        Product Description................................................................................................................................................................. 17
        Mechanism of Action ............................................................................................................................................................... 17
        R&D Progress ......................................................................................................................................................................... 17
    MultiStem..................................................................................................................................................................................... 18
        Product Description................................................................................................................................................................. 18
        Mechanism of Action ............................................................................................................................................................... 18
        R&D Progress ......................................................................................................................................................................... 18
Athersys, Inc. – Pipeline Analysis..................................................................................................................................................... 20
    Athersys, Inc. – Pipeline Products by Therapeutic Class ............................................................................................................ 20
    Athersys, Inc. - Pipeline Products By Target ............................................................................................................................... 21
    Athersys, Inc. – Pipeline Products by Route of Administration .................................................................................................... 22
    Athersys, Inc. – Pipeline Products by Molecule Type .................................................................................................................. 23
Athersys, Inc. – Recent Pipeline Updates ....................................................................................................................................... 24



Athersys, Inc. – Product Pipeline Review – H2 2011                                                                                      GMDHC02120CDB / Published DEC 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                      Page(2)
Athersys, Inc. – Product Pipeline Review



Athersys, Inc. - Dormant Projects ..................................................................................................................................................... 27
Athersys, Inc. – Company Statement ............................................................................................................................................... 28
Athersys, Inc. – Locations And Subsidiaries..................................................................................................................................... 32
    Head Office.................................................................................................................................................................................. 32
    Other Locations & Subsidiaries ................................................................................................................................................... 32
Company's Recent Developments ................................................................................................................................................... 33
    Athersys, Inc., Recent Developments.......................................................................................................................................... 33
        Jul 28, 2010: Athersys Announces Positive Results From Phase I Study Of Multistem In Heart Attack Patients ................... 33
        Feb 27, 2008: Athersys Announces Summary Results For Phase I Safety Study Of Its Novel Obesity Drug ATHX-105 ....... 35
        Jul 25, 2007: Athersys Initiates Phase I Trial For ATHX-105 For Treatment Of Obesity......................................................... 35
        May 25, 2011: Athersys Announces Positive Interim Results From Ongoing Phase I Study Of MultiStem For Hematopoietic
        Stem Cell Transplant Support And Graft-Versus-Host Disease .............................................................................................. 36
        Sep 23, 2010: Athersys Presents Phase I Study Data Of MultiStem In Heart Attack Patients At Transcatheter Cardiovascular
        Therapeutics Conference 2010 ............................................................................................................................................... 38
        Sep 23, 2008: Athersys Announces Update On ATHX-105 Development Plans And Results Of Recent Clinical Studies ..... 39
        Sep 21, 2010: Athersys Receives Orphan Drug Designation For MultiStem For Prevention Of Graft Versus Host Disease
        From FDA ............................................................................................................................................................................... 41
        Sep 20, 2010: Athersys Reports Data Showing Neuroprotective Effects Of MultiStem Therapy For Traumatic Brain Injury .. 42
        Jan 19, 2011: Researchers From Case Western Reserve And Athersys Publish Landmark Study Showing Regenerative
        Benefit of MultiStem Therapy After Spinal Cord Injury ............................................................................................................ 43
        Oct 17, 2011: Athersys Confirms Completion Of Patient Enrollment For Phase I Study Of MultiStem For Hematopoietic Stem
        Cell Transplant Support .......................................................................................................................................................... 44
        Feb 16, 2010: Athersys Completes Patient Enrollment In Phase I Study Of Multistem In Acute Myocardial Infarction .......... 45
        Mar 14, 2011: Athersys Initiates Patient Enrollment For Phase II Clinical Trial In Inflammatory Bowel Disease .................... 46
        Jun 13, 2011: Athersys Presents Positive Results From Phase I Clinical Trial Of MultiStem In Heart Attack Patients At
        International Stem Cell Symposium ........................................................................................................................................ 46
        Dec 11, 2008: Athersys Receives IND Authorization For Multistem In Treatment Of Ischemic Stroke ................................... 48
        Aug 10, 2006: Athersys Receives Approval To Begin Phase I Trial Of Lead Obesity Drug .................................................... 49
        Feb 10, 2011: Researchers From UTHealth And Athersys Present Preclinical Data Illustrating Potential Benefits Of
        MultiStem For Treating Stroke ................................................................................................................................................ 50
        Nov 08, 2010: Athersys Announces FDA Authorization Of Phase II Clinical Trial For Inflammatory Bowel Disease With Pfizer
        Regenerative Medicine ........................................................................................................................................................... 51
        Jan 06, 2011: Athersys Completes Patient Enrollment For Single Dose Arm Of MultiStem Phase I Study For Hematopoietic
        Stem Cell Transplant Support ................................................................................................................................................. 51
        Nov 04, 2011: Athersys Announces Publication Of Phase I Data Regarding MultiStem For Treating Acute Myocardial
        Infarction ................................................................................................................................................................................. 52
Financial Deals Landscape .............................................................................................................................................................. 54
    Athersys, Inc., Deals Summary ................................................................................................................................................... 54
Athersys, Inc., Pharmaceuticals & Healthcare, Deal Details ............................................................................................................ 55
    Venture Financing ....................................................................................................................................................................... 55
        Athersys Secures Late Stage Financing ................................................................................................................................. 55
    Partnerships ................................................................................................................................................................................ 56
        Athersys Enters Into Co-Development Agreement With Fast Forward ................................................................................... 56
        Athersys Enters Into Co-Development Agreement With Pfizer ............................................................................................... 58
        Athersys Enters Into An Agreement With Angiotech ............................................................................................................... 60
        Athersys Enters Into Co-Development Agreement With The National Institutes Of Health..................................................... 61
    Licensing Agreements ................................................................................................................................................................. 62



Athersys, Inc. – Product Pipeline Review – H2 2011                                                                                      GMDHC02120CDB / Published DEC 2011
©Global Markets Direct.. This report is a licensed product and is not to be photocopied                                                                                                       Page(3)
Athersys, Inc. – Product Pipeline Review



         Athersys Enters Into Licensing Agreement With Johnson & Johnson..............................................
								
To top